During a live event, Shuo Ma, MD, PhD, discussed the outcomes of the BRUIN trial of pirtobrutinib in BTK inhibitor–pretreated ...

THE001, a thermosensitive doxorubicin liposome for soft tissue sarcomas, received FDA orphan drug designation, offering ...

Branding in the health care industry should prioritize communicating empathy and care through every touchpoint.

With the progress in cancer treatments, we are increasingly achieving complete remission (CR) in more patients. Traditionally, CR has been defined as either a clinical CR, where symptoms and physical ...

In an interview with Targeted OncologyTM, Dong Chen, MD, PhD, hematopathologist and vice chair of practice in pathology in the Department of Laboratory Medicine and Pathology at Mayo Clinic in ...

Jack Khouri, MD, discusses data from a multicenter study of teclistamab in patients with relapsed/refractory multiple myeloma who had prior exposure to BCMA-directed therapy.

Panelists discuss how the choice between hydroxyurea (HU) and interferon (IFN) for cytoreductive therapy in polycythemia vera ...

Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.

Panelists discuss how patient education and multidisciplinary involvement are critical for early detection of chronic graft-vs-host disease (cGVHD).

Panelists discuss how steroid dosing for chronic graft-vs-host disease (cGVHD) typically starts at 0.5-1 mg/kg/day depending on severity, with careful tapering to avoid flares.

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...